Samsung Biologics signs vaccine deal with GreenLight Biosciences
Samsung Biologics signed a deal with GreenLight Biosciences to manufacture the Medford, Massachusetts-based pharmaceutical company's Covid-19 mRNA (messenger RNA) vaccine in Korea.
Under the contract manufacturing organization (CMO) deal, the two companies aim to cooperate in manufacturing the vaccines with the goal of distributing them to various countries, especially developing countries. GreenLight Biosciences plans to start Phase 1 clinical trials of the vaccine candidate in Africa in first half of 2022.
mRNA, or messenger ribonucleic acid, directs cells to create spike proteins, which trigger an immune response.
The Moderna and Pfizer Covid-19 vaccines use mRNA.
Samsung Biologics is building facilities to produce mRNA vaccines in its plant in Songdo, Incheon. The construction is expected to complete by April next year.
“We are delighted to partner with GreenLight to leverage our expertise in manufacturing a messenger RNA Covid-19 vaccine candidate to better serve patients in lower income countries,” John Rim, CEO of Samsung Biologics, said in Thursday’s statement. “This collaboration demonstrates a major milestone for Samsung Biologics as we will commence our expanded capabilities and operations to provide one-stop end-to-end messenger RNA production.”
BY SARAH CHEA [firstname.lastname@example.org]